Clinical Trial

Study of How People Make Decisions About Prostate Cancer Risk

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to learn about how the genetic risk modifier test affects people's thoughts and feelings.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-09-25; most recent amendment 2026-07-09.
Trial Details
NCT Number NCT07197723
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: CureBRCA Foundation
Conditions BRCA1/2, Geneitic Testing
Enrollment 150 participants
Start Date 2025-09-25
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-10